These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 27123882)

  • 1. Balancing treatment efficacy, toxicity and complication risk in elderly patients with metastatic renal cell carcinoma.
    van den Brom RR; van Es SC; Leliveld AM; Gietema JA; Hospers GA; de Jong IJ; de Vries EG; Oosting SF
    Cancer Treat Rev; 2016 May; 46():63-72. PubMed ID: 27123882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The evolving role of cytoreductive surgery for metastatic renal cell carcinoma.
    Chaudhary UB; Hull GW
    Oncology (Williston Park); 2003 May; 17(5):701-5; discussion 705-6, 711-2. PubMed ID: 12800795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytoreductive nephrectomy in metastatic renal cell carcinoma: the evolving role of surgery in the era of molecular targeted therapy.
    Kwan KG; Kapoor A
    Curr Opin Support Palliat Care; 2009 Sep; 3(3):157-65. PubMed ID: 19528804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Presurgical therapy in metastatic renal cell carcinoma.
    Jonasch E
    Expert Rev Anticancer Ther; 2007 Jan; 7(1):73-8. PubMed ID: 17187521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging therapeutic approaches in renal cell carcinoma.
    Parekh H; Rini BI
    Expert Rev Anticancer Ther; 2015; 15(11):1305-14. PubMed ID: 26376584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytoreductive nephrectomy in metastatic clear-cell renal cell carcinoma: perspectives in the tyrosine kinase inhibitor era.
    Biswas S; Kelly J; Eisen T
    Oncologist; 2009 Jan; 14(1):52-9. PubMed ID: 19147692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of elderly patients with metastatic renal cell carcinoma.
    Zanardi E; Grassi P; Cavo A; Verzoni E; Maggi C; De Braud F; Boccardo F; Procopio G
    Expert Rev Anticancer Ther; 2016; 16(3):323-34. PubMed ID: 26654225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune checkpoint blockade as a novel immunotherapeutic strategy for renal cell carcinoma: a review of clinical trials.
    Godwin JL; Zibelman M; Plimack ER; Geynisman DM
    Discov Med; 2014 Dec; 18(101):341-50. PubMed ID: 25549705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Evaluation of Response to Immunotherapy in Metastatic Renal Cell Carcinoma: Open Challenges in the Clinical Practice.
    Raimondi A; Randon G; Sepe P; Claps M; Verzoni E; de Braud F; Procopio G
    Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31480348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Immunotherapy for Renal Cell Carcinoma].
    Büchler T
    Klin Onkol; 2015; 28 Suppl 4():4S64-8. PubMed ID: 26647891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune checkpoint inhibitors as novel targets for renal cell carcinoma therapeutics.
    Bailey A; McDermott DF
    Cancer J; 2013; 19(4):348-52. PubMed ID: 23867517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metastatic renal cell carcinoma: systemic treatment.
    Abi-Aad AS; deKernion JB
    Acta Urol Belg; 1996 May; 64(2):3-8. PubMed ID: 8701805
    [No Abstract]   [Full Text] [Related]  

  • 13. Renal cell carcinoma.
    Rini BI; Campbell SC; Escudier B
    Lancet; 2009 Mar; 373(9669):1119-32. PubMed ID: 19269025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel targeted therapy for advanced renal carcinoma: trials in progress.
    Calabrò F; Sternberg CN
    Curr Opin Urol; 2010 Sep; 20(5):382-7. PubMed ID: 20625300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Interdisciplinary recommendations on targeted therapy in the treatment of renal cell carcinoma].
    Miller K; Bergmann L; Albers P; Jäger E; Jakse G; Geschwend JE; Marschner N
    Aktuelle Urol; 2007 Jul; 38(4):328-30. PubMed ID: 17647172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel immunotherapeutic strategies in development for renal cell carcinoma.
    Inman BA; Harrison MR; George DJ
    Eur Urol; 2013 May; 63(5):881-9. PubMed ID: 23084331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytoreductive surgery in the management of metastatic renal cell carcinoma: the UCLA experience.
    Franklin JR; Figlin R; Rauch J; Gitlitz B; Belldegrun A
    Semin Urol Oncol; 1996 Nov; 14(4):230-6. PubMed ID: 8946623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Role of surgery (cytoreductive nephrectomy and metastasectomy) in the management of metastatic renal cell carcinoma: a literature review].
    Arroua F; Maurin C; Carcenac A; Ragni E; Rossi D; Bastide C
    Prog Urol; 2010 Dec; 20(13):1175-83. PubMed ID: 21130395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytoreductive nephrectomy in metastatic renal cell carcinoma.
    Healy KA; Marshall FF; Ogan K
    Expert Rev Anticancer Ther; 2006 Aug; 6(8):1295-304. PubMed ID: 16925495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy in renal cell carcinoma.
    Bukowski RM
    Oncology (Williston Park); 1999 Jun; 13(6):801-10; discussion 810, 813. PubMed ID: 10378218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.